Drug Type Small molecule drug |
Synonyms Nalfurafine, Nalfurafine hydrochloride (JAN/USAN), Nopicor + [9] |
Target |
Mechanism κ opioid receptor agonists(Kappa opioid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (21 Jan 2009), |
RegulationOrphan Drug (KR) |
Molecular FormulaC28H33ClN2O5 |
InChIKeyDJSFYNINGIMKAG-FQJQBBMWSA-N |
CAS Registry152658-17-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06405 | Nalfurafine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pruritus | JP | 21 Jan 2009 | |
Pruritus | JP | 21 Jan 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic liver disease | Phase 3 | CN | 13 Oct 2023 | |
Chronic liver disease | Phase 3 | CN | 13 Oct 2023 | |
Chronic liver disease | Phase 3 | CN | 13 Oct 2023 | |
Uremic pruritus | Phase 3 | CN | 07 Sep 2020 | |
Kidney Failure, Chronic | Phase 2 | US | 01 Sep 2012 | |
Cancer Pain | Phase 2 | US | - | - |
Dermatitis, Atopic | Phase 1 | JP | - | - |
Neuralgia | Preclinical | JP | - | - |
Phase 2 | 45 | (MT-9938 2.5μg) | qnhvrgkvqv(zhougblkzt) = rcbreynlbn heexmaivsp (libjjgdcpb, xzgylplvul - wufmthpxvw) View more | - | 09 Feb 2022 | ||
(MT-9938 5μg) | qnhvrgkvqv(zhougblkzt) = ysvovprozf heexmaivsp (libjjgdcpb, bssnagsdhc - bebpgxxyzd) View more |